Age-Related Macular Degeneration

The newest version of ChatGPT accurately responded to most multiple-choice questions on ophthalmic cases but performed better on non-image–based questions.

A large language model demonstrated comparative diagnostic accuracy and completeness in glaucoma and retina disease to fellowship-trained ophthalmologists.

Test your knowledge with this clinician quiz! In this quiz, we test your knowledge on clinical assessment recommendations for patients with inherited retinal diseases based on 2022 guidelines from the American Academy of Ophthalmology.

In a phase 3 trial in China, QL1207 demonstrated equivalent efficacy to aflibercept with a similar safety profile for patients with nAMD.

Long-term anti-VEGF treatment for nAMD was linked to a reduction in mortality risk, with a slight increase in CVD risk, across 16-years of follow-up in Denmark.

Data from the phase 2 METforMIN trial do not support the use of oral metformin for reducing the progression of geographic atrophy.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our January 2024 month-in-review features crucial research on social determinants of health, updates on the latest ophthalmic pipeline developments, and a look at how the local environment affects eye health.

Pivotal clinical trials associated with FDA ophthalmic drug approval were found to underreport and conflate sex and gender in analysis.

Two-year XTEND trial data shows proactive aflibercept led to meaningful functional and anatomic improvements that were maintained across the study period.

A meta-analysis of RCTs revealed significant advantages with faricimab treatment in improving CST and reducing injection frequency among eyes with AMD or DME.

Results of the 76-week trial suggest that a treat-and-extend aflibercept regimen yields similar functional and anatomic outcomes as fixed dosing every 8 weeks among patients with nAMD.

Efficacy, pharmacokinetics, immunogenicity, and safety were comparable between patients receiving the aflibercept biosimilar SB15 and the reference drug.

Patients with retinal diseases found intravitreal anti-VEGF therapy and disease management challenging, but most expressed high levels of satisfaction with their treatment.

Based on the special protocol assessment submission, the company expects to begin the non-inferiority trial for the ophthalmic bevacizumab in the first quarter of 2024.

Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.

Higher vitamin B1 intake levels were associated with lower prevalence of late AMD in an analysis of NHANES data from 2005 to 2008.

A treat-and-extend regimen with aflibercept showed both anatomical and functional improvements for patients with nAMD and PCV during a two-year study.

Retina specialists discuss treatment and adherence strategies for patients with nAMD and DME. They also comment on the future of nAMD and DME management.

Retina specialists discuss factors to consider when selecting a therapy for patients with neovascular AMD and DME as well as loading-dose recommendations for select patients.

Retina specialists comment on switching patients from 2 mg to 8 mg of aflibercept for the management of neovascular age-related macular degeneration and diabetic macular edema and transitioning a patient who has good control with aflibercept to a newer therapy.

Metformin use was associated with a reduced likelihood of any AMD and dry AMD in a sample of patients without diabetes.

Ophthalmology registry data show increased macular fluid volume after initial treatment are associated with increased numbers of injections in nAMD treatment.

Factors associated with receiving eye care in past 12 months included a higher educational level and income, while food and housing insecurity were associated with not receiving eye care.

A qualitative study in Denmark explores the adherence of patients with nAMD to their treatment regimen despite various barriers, including access to care and poor health literacy.

The phase 3 trial results show brolucizumab had superior anatomic improvements compared to aflibercept, with no clinically meaningful differences in visual outcomes.

Nationwide data from Korea suggest abstinence from alcohol led to lower risks of clinical outcomes among patients with newly diagnosed open-angle glaucoma.

Of 1023 color fundus photograph images, the 5 optometrists in the study were able to accuracy diagnosis 226 images with AMD.

Outlook Therapeutics plans to resubmit the BLA for ophthalmic bevacizumab by the end of 2024, pending the successful completion of a required additional trial.

Ocuphire's end-of-phase 2 meeting with the FDA supports APX3330's phase 3 advancement, with 3-step worsening in binocular DRSS score as the primary endpoint.

Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.